How Metabolomics Uncovers Lipid Dysregulation in Alzheimer’s
Why Protein-Centric Alzheimer’s Research Has Fallen Short The pharmaceutical industry’s intensive focus on amyloid-beta and tau pathology in Alzheimer’s disease has yielded limited therapeutic success despite decades of investment and dozens of clinical...
Metabolomics for Quality Control in Natural Product Research
The expanding global herbal products market and increasing regulatory scrutiny have created unprecedented demands for robust quality control and standardization methodologies that transcend traditional single-marker approaches. While conventional quality control of...
Why MTAP Alone Falls Short for PRMT5 Patient Selection
Why Genetic Biomarkers Aren’t Enough for PRMT5 Patient Selection The PRMT5 inhibitor field is facing a patient selection crisis that’s quietly undermining billion-dollar drug development programs. While genomic biomarkers promised to revolutionize...